S100P can be used as a biomarker of the early development of PC; its expression level in PC and IPMN is significantly higher than in nontumor pancreatic tissues, and its expression level gradually increases with the grade of PanIN (60, 84–87). Here, S100P is linked to pancreatic intraductal papillary-mucinous neoplasm.